How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about amivantamab with lazertinib

Marketing authorisation indication

2.1

Amivantamab (Rybrevant, Janssen) with lazertinib (Lazcluze, Janssen) is indicated 'for the first‑line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations'.

Dosage in the marketing authorisation

Price

2.3

The price of amivantamab is £1,079 per 350 mg per 7‑ml vial (excluding VAT; BNF online accessed June 2025). The price of lazertinib for a pack of 56 80 mg tablets is £4,128.50, and for a pack of 28 240 mg tablets is £6,192.75 (company submission).

2.4

The company has a commercial arrangement for each technology, which would have applied if amivantamab plus lazertinib had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Johnson & Johnson will be included here when guidance is published.